Review of the clinical effectiveness and cost effectiveness of paclitaxel for ovarian cancer

This guidance has been partially updated by ‘Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review) (NICE technology appraisal guidance 91).

Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand.

• Review update
  For further information regarding this, please see the 'Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer' document under 'Background information'.

• Other information

  • TA55 Ovarian cancer - paclitaxel (review): guidance (Web format)
  • Summary: Guidance on the use of paclitaxel in the treatment of ovarian cancer

  How this guidance was produced

  Background information

  • Review Decision - October 2009
  • Review Proposal - August 2009
  • Decision of the Appeal Panel: Appraisal of Paclitaxel for Ovarian Cancer
  • Assessment Report: An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of ovarian cancer
  • 2003/004 Following planned review NICE issues updated guidance on paclitaxel for ovarian cancer
  • Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer
  • Media Briefing: Technology appraisal guidance on paclitaxel for ovarian cancer
  • Press statement: Review of NICE Technology Appraisal Guidance No.s 28, 45 and 55 - Topotecan, PLDH and paclitaxel for ovarian cancer

Guidance formats

• Web format
• Full Guidance (PDF)
• Patient version (PDF)

Ovarian cancer - paclitaxel (review)

Guideline for patients and carers (PDF)